Here's What Key Metrics Tell Us About Adaptive Biotechnologies (ADPT) Q2 Earnings

For the quarter ended June 2025, Adaptive Biotechnologies (ADPT) reported revenue of $58.88 million, up 36.3% over the same period last year. EPS came in at -$0.17, compared to -$0.26 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $49.7 million, representing a surprise of +18.47%. The company delivered an EPS surprise of +29.17%, with the consensus EPS estimate being -$0.24.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Adaptive Biotechnologies performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• ClonoSEQ test volume: 25,321 compared to the 24,035 average estimate based on three analysts.
• Revenues- Total Immune Medicine: $8.94 million versus $7.93 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +13.1% change.
• Revenues- MRD-Regulatory milestone: $5.5 million versus $1.28 million estimated by three analysts on average.
• Revenues- Total MRD: $49.94 million compared to the $42.33 million average estimate based on three analysts. The reported number represents a change of +41.5% year over year.
• Revenues- MRD-Service revenue: $44.44 million versus the three-analyst average estimate of $41.04 million.
• Revenues- Immune Medicine revenue- Collaboration: $3.94 million compared to the $4.07 million average estimate based on two analysts. The reported number represents a change of +124.1% year over year.
• Revenues- Immune Medicine revenue- Service: $5 million compared to the $4.59 million average estimate based on two analysts. The reported number represents a change of -18.7% year over year.

View all Key Company Metrics for Adaptive Biotechnologies here>>>

Shares of Adaptive Biotechnologies have returned -7.1% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
Adaptive Biotechnologies Corporation (ADPT): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research